{{Rsnum
|rsid=7691996
|Chromosome=4
|position=33728154
|Orientation=plus
|GMAF=0.2658
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 78.8 | 19.5 | 1.8
| HCB | 51.1 | 37.2 | 11.7
| JPT | 46.0 | 44.2 | 9.7
| YRI | 27.2 | 44.9 | 27.9
| ASW | 47.4 | 43.9 | 8.8
| CHB | 51.1 | 37.2 | 11.7
| CHD | 49.5 | 40.4 | 10.1
| GIH | 70.3 | 25.7 | 4.0
| LWK | 30.0 | 47.3 | 22.7
| MEX | 62.1 | 36.2 | 1.7
| MKK | 36.8 | 47.1 | 16.1
| TSI | 81.4 | 16.7 | 2.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7691996
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.15, combined P value= 1.48E-04. It is also associated with etoposide clearance.
|Drugs=etoposide
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470198
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7691996
|overall_frequency_n=33
|overall_frequency_d=126
|overall_frequency=0.261905
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=29
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}